Phase 3 Type 2 Diabetes Trial, Recruiting NCT07664553 Sponsor: AstraZeneca Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT07664553
Recruiting Phase 3 🇦🇺 Australian site

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with type 2 diabetes for at least 90 days before the screening visit
  • People who are on a stable treatment plan that includes background insulin and at least one other blood sugar-lowering medication
  • People whose HbA1c (a measure of average blood sugar levels over time) is between 7% and 10.5%
  • People with a body mass index (BMI) of 23 or higher at the time of screening
  • People whose body weight has been stable for at least 90 days before screening, based on self-reporting or medical records

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have type 1 diabetes, a secondary or congenital (inherited/birth-related) form of diabetes, or a history of diabetic ketoacidosis or hyperosmolar coma (serious diabetes-related emergencies)
  • People who are currently receiving, or expected to receive, treatment for diabetic eye disease (diabetic retinopathy) or fluid build-up in the eye (macular edema)
  • People who have had more than one episode of severe low blood sugar in the 180 days before screening, or who have difficulty recognising the warning signs of low blood sugar
  • People who have a significant medical condition affecting the upper digestive tract, or who regularly take medication that affects how the stomach moves or empties food
  • People with a history of inflammation of the pancreas (pancreatitis), either short-term or long-term
  • People with severe heart failure (the most serious level, known as NYHA Class IV)
  • People with a personal or family history of a specific type of thyroid cancer (medullary thyroid cancer) or a hereditary condition called multiple endocrine neoplasia type 2

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026

Contact this trial

Phone: 1-877-240-9479

Australian sites

Research Site, East Toowoomba,
Research Site, Parkville,
Research Site, St Leonards,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
6 July 2026
Est. completion
23 May 2028

Where this trial is recruiting

🇦🇺 Australia 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇳 China 🇨🇿 Czechia 🇩🇪 Germany 🇮🇳 India 🇯🇵 Japan 🇲🇾 Malaysia 🇵🇱 Poland 🇰🇷 South Korea 🇹🇭 Thailand 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change from baseline in Hemoglobin A1c (HbA1c)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov